Earnings Call Intelligence Subscribe
Home › Call Sheets › GILD › Q1'26
Call sheet · Q1'26

Gilead Sciences (GILD)

Q1'26 earnings call · held May 7, 2026 · compared with the Q4'25 call · management-credibility review
10/12
Disclosure score
2 medium, 4 low flags
Financial quality
Bottom line
The sleeper story everyone will miss: Gilead is destroying near-term EPS paying Dot-Com multiples for acquisitions, creating a 140-190% tax rate while the underlying business is actually accelerating. Yes2Go hitting $1B is the obvious headline, but management's evasion on persistency data ('it's early days') suggests their blockbuster bet might have retention issues. The binding constraint is execution risk across four simultaneous launches while integrating three major acquisitions. Most revealing quote: Johanna admitting 'we don't have an assumption' on persistency despite $1B guidance. My view changes if Yes2Go second-dose return rates come in below 70% or if Biclen cannibalizes more than 20% of Biktarvy switches.

The 30-second version

  • THE SLEEPER STORY: Gilead is burning $11.5B on acquisitions with 100%+ tax rates crushing EPS
  • Yes2Go upgraded to $1B from $800M but persistency data conveniently absent
  • Biktarvy growth decelerating to 7% while they prep a cannibalization product

What changed this quarter

MetricQ4'25Q1'26Change
Total Product Sales$7.9B (+5% YoY)$6.9B (+5% YoY)12% sequential decline, normal seasonality
HIV Sales$5.8B (+6% YoY)$5.0B (+10% YoY)400 bps growth acceleration
Biktarvy Sales$4.0B (+5% YoY)$3.4B (+7% YoY)200 bps growth acceleration
Yes2Go Sales$96M (Q4)$166M (+72% seq)Massive sequential acceleration
Descovy SalesNot disclosed Q4 only$807M (+38% YoY)Strong PrEP-driven growth
Trodelvy Sales$384M (+8% YoY)$402M (+37% YoY)290 bps growth acceleration
Cell Therapy Sales$458M (-6% YoY)$407M (-12% YoY)Deterioration accelerated 600 bps
Non-GAAP EPS$1.86$2.03 (+12% YoY)Strong operational performance
Operating MarginNot disclosed Q447%Top quartile margins maintained
R&D Expenses$1.6B (-3% YoY)$1.4B (flat YoY)Disciplined spending despite acquisitions

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full GILD Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.